References of "LANCELLOTTI, Patrizio"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailChronic ischemic mitral regurgitation
DULGHERU, Raluca Elena ULg; LANCELLOTTI, Patrizio ULg

in Applied echocardiography in coronary artery disease (in press)

Detailed reference viewed: 29 (4 ULg)
Full Text
Peer Reviewed
See detailProspective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
VROONEN, Laurent ULg; Lancellotti, Patrizio ULg; Garcia, Monica Tome et al

in Endocrine (2016)

Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid and effective hormonal and tumor control in most cases. Evidence of cardiac valvulopathy was demonstrated ... [more ▼]

Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid and effective hormonal and tumor control in most cases. Evidence of cardiac valvulopathy was demonstrated in Parkinson's disease patients treated with dopamine agonists. Retrospective studies in prolactinoma patients treated with cabergoline at lower doses did not show such an effect. However, few prospective data with long-term follow-up are available. The aim of this study was to assess the safety of cabergoline regarding cardiac valvular status during prospective follow-up in patients treated for prolactinoma or idiopathic hyperprolactinemia. We report here a series of 100 patients (71F; median age at diagnosis: 41.5 years) treated with cabergoline for endocrine diseases (prolactinoma n = 89, idiopathic hyperprolactinemia n = 11). All patients underwent complete transthoracic echocardiographic studies at baseline and during long-term prospective surveillance using the same equipment and performed by the same technicians. The median interval between baseline and last follow-up echocardiographic studies while on cabergoline was 62.5 months (interquartile range: 34.75-77.0). The median total duration of cabergoline treatment was 124.5 months (interquartile range: 80.75-188.75) and the median cumulative total dose of cabergoline was 277.8 mg (interquartile range : 121.4-437.8 mg) at last follow-up. We found no clinically relevant alterations in cardiac valve function or valvular calcifications with cabergoline treatment. Our data suggest that findings from retrospective analyses are correct and that cabergoline is a safe chronic treatment at the doses used typically in endocrinology. [less ▲]

Detailed reference viewed: 13 (2 ULg)
Peer Reviewed
See detailHeart Team Liege - Session Video Link
PIERARD, Luc ULg; vahanian, Alec; LANCELLOTTI, Patrizio ULg et al

Conference (2016, September)

Detailed reference viewed: 62 (1 ULg)
Peer Reviewed
See detailHeart Team Session
PIERARD, Luc ULg; LANCELLOTTI, Patrizio ULg; PETERMANS, Jean ULg et al

Conference (2016, August)

Detailed reference viewed: 22 (3 ULg)
Full Text
Peer Reviewed
See detailNormal reference values for echocardiography: a call for comparison between ethnicities.
Cosyns, Bernard; LANCELLOTTI, Patrizio ULg

in European Heart Journal - Cardiovascular Imaging (2016), 17(5), 523-4

Detailed reference viewed: 19 (6 ULg)
Full Text
Peer Reviewed
See detailEACVI appropriateness criteria for the use of cardiovascular imaging in heart failure derived from European National Imaging Societies voting.
Garbi, Madalina; Edvardsen, Thor; Bax, Jeroen et al

in European heart journal cardiovascular Imaging (2016)

This paper presents the first European appropriateness criteria for the use of cardiovascular imaging in heart failure, derived from voting of the European National Imaging Societies representatives. The ... [more ▼]

This paper presents the first European appropriateness criteria for the use of cardiovascular imaging in heart failure, derived from voting of the European National Imaging Societies representatives. The paper describes the development process and discusses the results. [less ▲]

Detailed reference viewed: 16 (3 ULg)
Full Text
Peer Reviewed
See detailMalignant Mitral Valve Prolapse: Substrates to Ventricular Remodeling and Arrhythmias.
LANCELLOTTI, Patrizio ULg; Garbi, Madalina

in Circulation: Cardiovascular Imaging (2016), 9(8), 005248

Detailed reference viewed: 17 (3 ULg)
Full Text
Peer Reviewed
See detailCalcific aortic stenosis.
Lindman, Brian R.; Clavel, Marie-Annick; Mathieu, Patrick et al

in Nature Reviews. Disease Primers (2016), 2

Calcific aortic stenosis (AS) is the most prevalent heart valve disorder in developed countries. It is characterized by progressive fibro-calcific remodelling and thickening of the aortic valve leaflets ... [more ▼]

Calcific aortic stenosis (AS) is the most prevalent heart valve disorder in developed countries. It is characterized by progressive fibro-calcific remodelling and thickening of the aortic valve leaflets that, over years, evolve to cause severe obstruction to cardiac outflow. In developed countries, AS is the third-most frequent cardiovascular disease after coronary artery disease and systemic arterial hypertension, with a prevalence of 0.4% in the general population and 1.7% in the population >65 years old. Congenital abnormality (bicuspid valve) and older age are powerful risk factors for calcific AS. Metabolic syndrome and an elevated plasma level of lipoprotein(a) have also been associated with increased risk of calcific AS. The pathobiology of calcific AS is complex and involves genetic factors, lipoprotein deposition and oxidation, chronic inflammation, osteoblastic transition of cardiac valve interstitial cells and active leaflet calcification. Although no pharmacotherapy has proved to be effective in reducing the progression of AS, promising therapeutic targets include lipoprotein(a), the renin-angiotensin system, receptor activator of NF-kappaB ligand (RANKL; also known as TNFSF11) and ectonucleotidases. Currently, aortic valve replacement (AVR) remains the only effective treatment for severe AS. The diagnosis and staging of AS are based on the assessment of stenosis severity and left ventricular systolic function by Doppler echocardiography, and the presence of symptoms. The introduction of transcatheter AVR in the past decade has been a transformative therapeutic innovation for patients at high or prohibitive risk for surgical valve replacement, and this new technology might extend to lower-risk patients in the near future. [less ▲]

Detailed reference viewed: 17 (1 ULg)
Full Text
Peer Reviewed
See detailCan multiple previous treatment-requiring rejections affect biventricular myocardial function in heart transplant recipients? A two-dimensional speckle-tracking study.
Romano, Giuseppe; Raffa, Giuseppe Maria; Licata, Pamela et al

in International Journal of Cardiology (2016), 209

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailEuroEcho-Imaging 2015: highlights.
Magne, Julien; Popescu, Bogdan A.; Cosyns, Bernard et al

in European Heart Journal - Cardiovascular Imaging (2016), 17(6), 596-603

The annual meeting of the European Association of Cardiovascular Imaging, EuroEcho-Imaging, was held in Seville, Spain, in December 2015. In the present paper, we present a summary of the 'Highlights ... [more ▼]

The annual meeting of the European Association of Cardiovascular Imaging, EuroEcho-Imaging, was held in Seville, Spain, in December 2015. In the present paper, we present a summary of the 'Highlights' session. [less ▲]

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailRole of a heart valve clinic programme in the management of patients with aortic stenosis.
Zilberszac, Robert; Lancellotti, Patrizio ULg; Gilon, Dan et al

in European Heart Journal - Cardiovascular Imaging (2016)

AIMS: We sought to assess the efficacy of a heart valve clinic (HVC) follow-up programme for patients with severe aortic stenosis (AS). METHODS AND RESULTS: Three hundred and eighty-eight consecutive ... [more ▼]

AIMS: We sought to assess the efficacy of a heart valve clinic (HVC) follow-up programme for patients with severe aortic stenosis (AS). METHODS AND RESULTS: Three hundred and eighty-eight consecutive patients with AS (age 71 +/- 10 years; aortic-jet velocity 5.1 +/- 0.6 m/s) and an indication for aortic valve replacement (AVR) were included. Of these, 290 patients presented with an indication for surgery at their first visit at the HVC and 98 asymptomatic patients who had been enrolled in an HVC monitoring programme developed indications for surgery during follow-up. Time to symptom detection was significantly longer in patients that presented with symptoms at baseline (352 +/- 471 days) than in patients followed in the HVC (76 +/- 75 days, P < 0.001). Despite being educated to recognize and promptly report new symptoms, 77 of the 98 patients in the HVC programme waited until the next scheduled consultation to report them. Severe symptom onset (NYHA or CCS Class >/=III) was present in 61% of patients being symptomatic at the initial visit and in 34% of patients in the HVC programme (P < 0.001). CONCLUSION: Delays in referral and symptom reporting as well as symptom denial are common in patients with AS. These findings support the concept of risk stratification to identify patients who may benefit from elective surgery. A structured HVC programme results in the detection of symptoms at an earlier and less severe stage and thus in an optimized timing of surgery. [less ▲]

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailPredicting Reversibility of Anticancer Drugs-Related Cardiac Dysfunction: A New Piece to the Routine Use of Deformation Imaging.
Lancellotti, Patrizio ULg; Moonen, Marie; Jerusalem, Guy ULg

in Echocardiography (Mount Kisco, N.Y.) (2016), 33(4), 504-9

Detailed reference viewed: 19 (2 ULg)
Full Text
Peer Reviewed
See detailRecommendations for the imaging assessment of prosthetic heart valves: a report from the European Association of Cardiovascular Imaging endorsed by the Chinese Society of Echocardiography, the Inter-American Society of Echocardiography, and the Brazilian Department of Cardiovascular Imaging.
Lancellotti, Patrizio ULg; Pibarot, Philippe; Chambers, John et al

in European heart journal cardiovascular Imaging (2016)

Prosthetic heart valve (PHV) dysfunction is rare but potentially life-threatening. Although often challenging, establishing the exact cause of PHV dysfunction is essential to determine the appropriate ... [more ▼]

Prosthetic heart valve (PHV) dysfunction is rare but potentially life-threatening. Although often challenging, establishing the exact cause of PHV dysfunction is essential to determine the appropriate treatment strategy. In clinical practice, a comprehensive approach that integrates several parameters of valve morphology and function assessed with 2D/3D transthoracic and transoesophageal echocardiography is a key to appropriately detect and quantitate PHV dysfunction. Cinefluoroscopy, multidetector computed tomography, cardiac magnetic resonance imaging, and to a lesser extent, nuclear imaging are complementary tools for the diagnosis and management of PHV complications. The present document provides recommendations for the use of multimodality imaging in the assessment of PHVs. [less ▲]

Detailed reference viewed: 40 (2 ULg)
Full Text
Peer Reviewed
See detailLeft ventricular regional function and maximal exercise capacity in aortic stenosis.
DULGHERU, Raluca Elena ULg; Magne, Julien; DAVIN, Laurent ULg et al

in European Heart Journal - Cardiovascular Imaging (2016)

AIMS: The objective assessment of maximal exercise capacity (MEC) using peak oxygen consumption (VO2) measurement may be helpful in the management of asymptomatic aortic stenosis (AS) patients. However ... [more ▼]

AIMS: The objective assessment of maximal exercise capacity (MEC) using peak oxygen consumption (VO2) measurement may be helpful in the management of asymptomatic aortic stenosis (AS) patients. However, the relationship between left ventricular (LV) function and MEC has been relatively unexplored. We aimed to identify which echocardiographic parameters of LV systolic function can predict MEC in asymptomatic AS. METHODS AND RESULTS: Asymptomatic patients with moderate to severe AS (n = 44, aortic valve area <1.5 cm2, 66 +/- 13 years, 75% of men) and preserved LV ejection fraction (LVEF > 50%) were prospectively referred for resting echocardiography and cardiopulmonary exercise test. LV longitudinal strain (LS) of each myocardial segment was measured by speckle tracking echocardiography (STE) from the apical (aLS) 4-, 2-, and 3-chamber views. An average value of the LS of the analysable segments was provided for each myocardial region: basal (bLS), mid (mLS), and aLS. LV circumferential and radial strains were measured from short-axis views. Peak VO2 was 20.1 +/- 5.8 mL/kg/min (median 20.7 mL/kg/min; range 7.2-32.3 mL/kg/min). According to the median of peak VO2, patients with reduced MEC were significantly older (P < 0.001) and more frequently females (P = 0.05). There were significant correlations between peak VO2 and age (r = -0.44), LV end-diastolic volume (r = 0.35), LV stroke volume (r = 0.37), indexed stroke volume (r = 0.32), and E/e' ratio (r = -0.37, all P < 0.04). Parameters of AS severity and LVEF did not correlate with peak VO2 (P = NS for all). Among LV deformation parameters, bLS and mLS were significantly associated with peakVO2 (r = 0.43, P = 0.005, and r = 0.32, P = 0.04, respectively). With multivariable analysis, female gender (beta = 4.9; P = 0.008) and bLS (beta = 0.50; P = 0.03) were the only independent determinants (r2 = 0.423) of peak VO2. CONCLUSION: In asymptomatic AS, impaired LV myocardial longitudinal function determines reduced MEC. Basal LS was the only parameter of LV regional function independently associated with MEC. [less ▲]

Detailed reference viewed: 88 (21 ULg)
Full Text
Peer Reviewed
See detailQuantification of paravalvular regurgitation after transcatheter aortic valve implantation: improved accuracy means better standardization.
Lancellotti, Patrizio ULg; Piazza, Nicolo; Modine, Thomas

in European Heart Journal - Cardiovascular Imaging (2016)

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailThe clinical challenge of concomitant aortic and mitral valve stenosis.
Unger, Philippe; Lancellotti, Patrizio ULg; de Canniere, Didier

in Acta Cardiologica (2016), 71(1), 3-6

The coexistence of mitral and aortic stenosis is not exceptional. Whereas rheumatic fever is currently plummeting in the Western countries, the incidence of degenerative disease is inversely increasing ... [more ▼]

The coexistence of mitral and aortic stenosis is not exceptional. Whereas rheumatic fever is currently plummeting in the Western countries, the incidence of degenerative disease is inversely increasing. The haemodynamic interactions which may interfere both with the usual echocardiographic parameters and with the invasive assessment may render the diagnosis difficult. The therapeutic challenges raised by this entity should not be underestimated. The increased morbidity and mortality of multivalvular surgery has to be balanced with the risk of a second operation down the line if one valvular involvement, deemed of a lesser importance, is neglected. This complex situation requires the multidisciplinary approach of a heart team involving surgeons, cardiologists, geriatrists if need be and imaging specialists. [less ▲]

Detailed reference viewed: 10 (0 ULg)